Navigation Links
Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Date:1/9/2012

ALBUQUERQUE, N.M., Jan. 9, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the launch of Avise SLE, which aids in the diagnosis of lupus (Systemic Lupus Erythematosus).

Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE diagnosis. Specifically, the panel includes testing of ANA, dsDNA, Avise MCV, EC4d and BC4d. The Avise SLE diagnostic differentiates itself by using cell-bound complements because of their increased performance over soluble complements which helps to accurately and consistently diagnose SLE.

Avise SLE is most impactful when ordered as a first step in patient treatment to help physicians with diagnosis by providing:

  • Efficiency - 5 individual markers, 1 blood draw
  • Confidence in Diagnosis - From a panel that rules-in SLE and rules-out other rheumatic diseases
  • Increased Accuracy - Using CB-CAPs technology to achieve 78% sensitivity and 87% specificity for other diseases/97% specificity for normal/healthy patients
  • Convenience - We provide kits, pay shipping costs and return test results in 7 business days

 

"Exagen is excited to offer a breakthrough diagnostic that uses CB-CAPs technology to help accurately determine if a patient has lupus," said Ron Rocca, President and CEO. "Because diagnosing lupus is so difficult and early diagnosis is critical in avoiding major organ damage, developing an accurate diagnostic to fill the unmet need for rheumatologists was a top priority. We have been able to do that with Avise SLE and are pleased to take part in helping physicians gain control over this serious disease."

About Exagen

Exagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA registered, CAP certified laboratory with a growing menu of proprietary, internally developed tests focused in the areas of Rheumatology and Gastroenterology. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management.  Using uniquely powerful Coperna® discovery technology, Exagen identifies and validates small sets of genomic markers which are used to create meaningful, easily interpreted diagnostic tests for clinical use. For more information, please visit www.Exagen.com or www.AviseTest.com.


'/>"/>
SOURCE Exagen Diagnostics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Eric Tornoe Joins Exagen Diagnostics as President and COO
2. Exagen Diagnostics Awarded $400,000 in Grants Under the QTDP Program
3. SuperNova Diagnostics® to Present at Biotech Showcase™ 2012 During JP Morgan Healthcare Conference January 9 - 12
4. S.E.D. Labs to be Acquired by Quest Diagnostics
5. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
6. SuperNova Diagnostics® to Present at the 23rd Annual Piper Jaffray Healthcare Conference in New York City
7. Quest Diagnostics CE Marks Simplexa™ Test for Cytomegalovirus for Sale in Europe
8. Quest Diagnostics Encourages Denver Area Residents to Enroll in Historic American Cancer Society Prevention Study November 8th - 19th
9. Quest Diagnostics Initiates CEO Succession Process
10. Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
11. Ambry Genetics First to Offer Exome Sequencing Service for Clinical Diagnostics.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2016)... York , May 6, 2016 ... Research " Molecular Diagnostic Market for Group A Streptococcus (GAS) ... Size, Share, Growth, Trends, and Forecast, 2015 - 2023 ", ... group A streptococcus (GAS) nucleic acid (NA) test products market ... projected to expand at a CAGR of 11.6% from 2015 ...
(Date:5/5/2016)... Atlanta, Georgia (PRWEB) , ... May 05, 2016 ... ... Patent and Trademark Office has granted two additional patents, U.S. Patent Nos. 9,322,133 ... These patents cover processes for making nanocellulose as well as hydrophobic nanocellulose compositions. ...
(Date:5/4/2016)... ... May 04, 2016 , ... Proove Biosciences, Inc. , the ... partnership with McGill University . The partnership is designed to advance research in ... to help patients in pain. With the new agreement, researchers at Proove Biosciences are ...
(Date:5/4/2016)... ... May 04, 2016 , ... Nutrafol®, a first-to-market smart-supplement ... hormonal and stress related hair loss. With patent-pending formulas for both female hair ... leaders in the medical and salon channels nationwide. , Dermatologists, Plastic Surgeons ...
Breaking Biology Technology:
(Date:3/9/2016)... Nigeria . Recently, ... 23,000 public service employees either did not exist with ... unlawfully.    --> Nigeria . ... than 23,000 public service employees either did not exist ... salary unlawfully.    --> DERMALOG, the biometrics ...
(Date:3/3/2016)... Calif. , March 3, 2016  FlexTech, a ... the categories of Innovation, Research & Development, Leadership in ... Leadership. This is the 9 th year of ... group of companies and individuals from past years ... based on a pre-described set of criteria, by a ...
(Date:3/2/2016)... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ... "Global Biometrics Market in Hospitality Sector 2016-2020" ... , , Global biometrics market in the ... of around 27%   --> ... addition of the  "Global Biometrics Market in ...
Breaking Biology News(10 mins):